RNF180 Septin9 Methylation Detection Kit Gastric Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting abnormal cell proliferation, such as gastric cancer, often face challenges in distinguishing between gastritis and gastric cancer, leading to delayed treatment due to lack of sensitivity and specificity, and existing gene detection methods are not sufficiently non-invasive or rapid.
Innovation Solution
A gene composition and kit that detect methylation levels in the RNF180 and Septin9 genes using bisulfite treatment and PCR, allowing for the differentiation between normal, gastritis, and gastric cancer through the analysis of methylation levels in biological samples, with the kit comprising nucleic acids, primers, and probes designed to hybridize specifically to target sequences.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional detection methods are used to detect abnormal cell proliferation, then the detection can be performed, but the sensitivity and specificity are insufficient leading to inability to distinguish between gastritis and gastric cancer
Solution Approach 1:
The patent divides the detection target into multiple specific gene regions (CpG islands) within the RNF180 and Septin9 genes. By segmenting the detection into specific methylation regions rather than overall gene expression, the method achieves higher precision in distinguishing cancerous from inflammatory conditions.
Solution Approach 2:
The patent detects abnormal cell proliferation by measuring changes in methylation parameters (methylation levels) of specific gene regions. This parameter-based approach allows for sensitive differentiation between gastritis and gastric cancer, improving both detection precision and diagnostic reliability.
2Measurement precision
If gene detection methods are used to improve detection accuracy, then sensitivity and specificity increase, but the methods are not sufficiently non-invasive or rapid
Solution Approach 1:
The patent uses methylation status as an intermediary marker to indirectly detect abnormal cell proliferation. Instead of directly analyzing cancer cells through invasive biopsy, the method detects methylation changes in accessible samples (blood, stool, urine) that serve as proxies for tumor presence, achieving both accuracy and non-invasiveness.
Solution Approach 2:
The patent replaces mechanical tissue biopsy with molecular detection methods analyzing methylation patterns in body fluids. This substitution eliminates the need for invasive procedures while maintaining high detection accuracy through biochemical analysis of methylation status.
3Reliability
If multiple gene markers are combined for detection, then sensitivity and specificity improve, but the detection complexity increases
Solution Approach 1:
The patent combines detection of methylation status from multiple gene markers (RNF180 and Septin9) into a unified detection system. By merging these markers, the method achieves higher diagnostic reliability through complementary information while managing complexity through integrated analysis protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a non-invasive and rapid means to accurately diagnose and grade gastric cancer and gastritis, improving sensitivity and specificity by combining the detection of Septin9 and RNF180 biomarkers, enabling early detection and differentiation between normal, inflammatory, and cancerous conditions.
Implementation Method 1
The composition further comprises a reagent that converts 5-unmethylated cytosine base of a gene to uracil or other base that is detectably different from cytosine in terms of hybridization performance
Implementation Method 2
the kit comprising nucleic acids, primers, and probes designed to hybridize specifically to target sequences
Data Source
AI summary
The present invention provides a composition, a kit and the use thereof, as well as the method for detecting the cell proliferative abnormality in individuals or grading the disease degree in the individuals. The composition comprises nucleic acids for detecting the methylation level within at least one target region of a gene and the fragment thereof.